75 results on '"Ritchlin, C. T."'
Search Results
2. POS1526 TREATMENT EFFECTS OF IXEKIZUMAB AND ADALIMUMAB AT THE INDIVIDUAL DIGIT LEVEL WITH NAIL AND DISTAL INTERPHALANGEAL JOINT INVOLVEMENT IN PATIENTS WITH PSORIATIC ARTHRITIS
Catalog
Books, media, physical & digital resources
3. POS1543 EFFICACY OF RISANKIZUMAB IN THE TREATMENT OF PsA PATIENTS WITH LIMITED AND EXTENSIVE JOINT INVOLVEMENT
4. AB1099 SUSTAINED EFFICACY OF BIMEKIZUMAB TREATMENT ASSESSED USING COMPOSITE DISEASE ACTIVITY MEASURES IN PATIENTS WITH PSORIATIC ARTHRITIS AND PRIOR INADEQUATE RESPONSE OR INTOLERANCE TO TUMOUR NECROSIS FACTOR INHIBITORS: RESULTS FROM THE PHASE 3 BE COMPLETE STUDY AND ITS OPEN LABEL EXTENSION UP TO 1 YEAR
5. POS0231 SUSTAINED EFFICACY AND SAFETY OF BIMEKIZUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND PRIOR INADEQUATE RESPONSE TO TUMOUR NECROSIS FACTOR INHIBITORS: RESULTS FROM THE PHASE 3 BE COMPLETE STUDY AND ITS OPEN-LABEL EXTENSION UP TO 1 YEAR
6. AB1095 IMPACT OF PSORIATIC ARTHRITIS MANIFESTATIONS ON PERCEPTION OF PAIN IMPROVEMENT: POOLED ANALYSIS OF TWO PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDIES WITH GUSELKUMAB
7. POS1531 GUSELKUMAB, AN IL-23P19 SUBUNIT–SPECIFIC MONOCLONAL ANTIBODY, BINDS CD64+ MYELOID CELLS AND POTENTLY NEUTRALISES IL-23 PRODUCED FROM THE SAME CELLS
8. POS0019 PREDICTION OF PSORIATIC ARTHRITIS TOOL (PRESTO): DEVELOPMENT AND PERFORMANCE OF A NEW SCORING SYSTEM FOR PSORIATIC ARTHRITIS RISK
9. AB1104 STRINGENT DISEASE ACTIVITY CONTROL AT 2 YEARS ACROSS PSORIATIC ARTHRITIS DOMAINS IRRESPECTIVE OF BASELINE CHARACTERISTICS IN PATIENTS TREATED WITH GUSELKUMAB: POST-HOC ANALYSIS OF A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
10. Efficacy of guselkumab, a selective IL-23 inhibitor, in Preventing Arthritis in a Multicentre Psoriasis At-Risk cohort (PAMPA): protocol of a randomised, double-blind, placebo controlled multicentre trial
11. Supplementary to: Psoriatic arthritis.
12. POS1028 GUSELKUMAB MAINTAINS RESOLUTION OF DACTYLITIS AND ENTHESITIS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: RESULTS THROUGH 2 YEARS FROM A PHASE 3 STUDY
13. POS1070 BASELINE DETERMINANTS OF PAIN RESPONSE IN PATIENTS WITH PSORIATIC ARTHRITIS RECEIVING GUSELKUMAB
14. POS0005 BASELINE BIOMARKERS PREDICT BETTER RESPONSES TO DEUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 (TYK2) INHIBITOR, IN A PHASE 2 TRIAL IN PSORIATIC ARTHRITIS
15. OP0255 BIMEKIZUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND AN INADEQUATE RESPONSE TO TUMOUR NECROSIS FACTOR INHIBITORS: 16-WEEK EFFICACY & SAFETY FROM BE COMPLETE, A PHASE 3, MULTICENTRE, RANDOMISED PLACEBO-CONTROLLED STUDY
16. LB0001 BIMEKIZUMAB IN BDMARD-NAIVE PATIENTS WITH PSORIATIC ARTHRITIS: 24-WEEK EFFICACY & SAFETY FROM BE OPTIMAL, A PHASE 3, MULTICENTRE, RANDOMISED, PLACEBO-CONTROLLED, ACTIVE REFERENCE STUDY
17. POS1022 RELATIONSHIPS BETWEEN INHIBITION OF RADIOGRAPHIC PROGRESSION AND ACHIEVEMENT OF LOW DISEASE ACTIVITY OR REMISSION AND THEIR CORE COMPONENTS IN PATIENTS WITH PSORIATIC ARTHRITIS TREATED WITH SECUKINUMAB IN FUTURE 5 DURING THE FIRST 24 WEEKS
18. POS1016 RELATIONSHIPS BETWEEN DISEASE DURATION AND RADIOGRAPHIC PROGRESSION AMONG PATIENTS WITH PSORIATIC ARTHRITIS TREATED WITH SECUKINUMAB IN FUTURE 5
19. AB0887 Designing a Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Investigate the Effect of Guselkumab Dosing Interval in Psoriatic Arthritis Patients with Inadequate Response to Tumor Necrosis Factor Inhibition
20. AB0896 Comparative Effectiveness of Guselkumab in Psoriatic Arthritis: Updates to a Systematic Literature Review and Network Meta-Analysis
21. AB0924 Individual Digit Level Nail Involvement and Joint Assessment in Patients with Nail Psoriasis
22. Does biologic therapy impact the development of PsA among patients with psoriasis?
23. OP0030 TREATMENT OF NON-BIOLOGIC-DMARD-IR PSA PATIENTS WITH UPADACITINIB OR ADALIMUMAB RESULTS IN THE MODULATION OF DISTINCT FUNCTIONAL PATHWAYS: PROTEOMICS ANALYSIS OF THE SELECT-PSA 1 PHASE 3 STUDY
24. POS1035 UPADACITINIB AS MONOTHERAPY AND IN COMBINATION WITH NON-BIOLOGIC DMARDs FOR THE TREATMENT OF PSORIATIC ARTHRITIS: SUBGROUP ANALYSIS FROM TWO PHASE 3 TRIALS
25. AB0550 EFFICACY OF UPADACITINIB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND A LOW OR HIGH SWOLLEN JOINT COUNT: A SUBGROUP ANALYSIS OF 2 PHASE 3 STUDIES (SELECT-PsA 1 AND SELECT-PsA 2)
26. AB0525 GUSELKUMAB TREATMENT SHOWS RAPID ONSET OF EFFECT ON COMPONENTS OF AMERICAN COLLEGE OF RHEUMATOLOGY RESPONSE CRITERIA: RESULTS OF 2 RANDOMIZED PHASE 3 TRIALS
27. AB0528 COMPARABLE SAFETY PROFILE OF GUSELKUMAB IN PSORIATIC ARTHRITIS AND PSORIASIS: RESULTS FROM PHASE 3 TRIALS THROUGH 1 YEAR
28. POS1024 GUSELKUMAB PROVIDES SUSTAINED DOMAIN-SPECIFIC AND COMPREHENSIVE EFFICACY AS ASSESSED USING COMPOSITE ENDPOINTS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS
29. POS1036 COLLAGEN TURNOVER MARKERS ARE ASSOCIATED WITH ACTIVE PSORIATIC ARTHRITIS AND DECREASE WITH GUSELKUMAB TREATMENT IN A PHASE-3 CLINICAL TRIAL
30. AB0538 POOLED SAFETY RESULTS FROM TWO PHASE-3 TRIALS OF GUSELKUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS THROUGH 1 YEAR
31. POS0407 PROTEOMICS ANALYSIS COMPARING THE MODE OF ACTION OF UPADACITINIB BETWEEN NON-BIOLOGIC-DMARD-IR AND BIOLOGIC-DMARD-IR PsA PATIENTS IDENTIFIES DISTINCT PATHOGENIC PATHWAYS IN THE SELECT-PsA 1 AND SELECT-PsA 2 PHASE 3 STUDIES
32. POS1022 BIMEKIZUMAB SAFETY AND EFFICACY IN PATIENTS WITH PSORIATIC ARTHRITIS: 3-YEAR RESULTS FROM A PHASE 2b OPEN-LABEL EXTENSION STUDY
33. POS1029 GUSELKUMAB-TREATED PATIENTS WITH PSORIATIC ARTHRITIS ACHIEVED CLINICALLY MEANINGFUL IMPROVEMENTS IN GENERAL HEALTH OUTCOMES MEASURED WITH PROMIS-29 THROUGH 52 WEEKS: RESULTS FROM THE PHASE 3 DISCOVER-1 TRIAL
34. POS0195 GUSELKUMAB TREATMENT MODULATES CORE PSORIATIC ARTHRITIS GENE EXPRESSION IN TWO PHASE 3 CLINICAL TRIALS (DISCOVER-1 AND -2)
35. AB0526 SUSTAINED GUSELKUMAB RESPONSE IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS REGARDLESS OF BASELINE DEMOGRAPHIC AND DISEASE CHARACTERISTICS: POOLED RESULTS THROUGH WEEK 52 OF TWO PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED STUDIES
36. Association between focal erosions and generalised bone loss in psoriatic arthritis
37. SAT0403 EFFICACY AND SAFETY OF 108 WEEKS’ BIMEKIZUMAB TREATMENT IN PATIENTS WITH PSORIATIC ARTHRITIS: INTERIM RESULTS FROM A PHASE 2 OPEN-LABEL EXTENSION STUDY
38. AB0801 EFFECTS OF GUSELKUMAB, A MONOCLONAL ANTIBODY THAT SPECIFICALLY BINDS TO THE P19-SUBUNIT OF INTERLEUKIN-23, ON DACTYLITIS AND ENTHESITIS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: POOLED RESULTS THROUGH WEEK 24 FROM TWO PHASE 3 STUDIES
39. FRI0359 INTEGRATED SAFETY RESULTS OF TWO PHASE-3 TRIALS OF GUSELKUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS THROUGH THE PLACEBO-CONTROLLED PERIODS
40. FRI0355 IMPACT OF BIOLOGIC THERAPY ON THE INCIDENCE OF PSA AMONG PATIENTS WITH PSORIASIS
41. SAT0397 GUSELKUMAB, AN IL-23 INHIBITOR THAT SPECIFICALLY BINDS TO THE IL23P19-SUBUNIT, FOR ACTIVE PSORIATIC ARTHRITIS: ONE YEAR RESULTS OF A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF PATIENTS WHO WERE BIOLOGIC-NAÏVE OR TNFΑ INHIBITOR-EXPERIENCED
42. SAT0417 TILDRAKIZUMAB EFFICACY ON PSORIASIS IN PATIENTS WITH PSORIATIC ARTHRITIS—A 52-WEEK ANALYSIS FROM A PHASE 2 STUDY
43. OP0227 SECUKINUMAB VERSUS ADALIMUMAB HEAD-TO-HEAD COMPARISON IN BIOLOGIC-NAÏVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS THROUGH 52-WEEKS (EXCEED): A RANDOMISED, DOUBLE-BLIND, PHASE-3B STUDY
44. AB0813 GUSELKUMAB-TREATED PATIENTS ACHIEVED CLINICALLY MEANINGFUL IMPROVEMENT IN SYSTEMIC SYMPTOMS AS MEASURED WITH PROMIS INSTRUMENT: RESULTS FROM PHASE-3 PSORIATIC ARTHRITIS TRIAL DISCOVER 1
45. AB0827 IMPACT OF BASELINE BODY MASS INDEX ON THE EFFICACY AND SAFETY OF TOFACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS
46. AB0820 COMPARATIVE EFFICACY OF GUSELKUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS: RESULTS FROM SYSTEMATIC LITERATURE REVIEW AND NETWORK META-ANALYSIS
47. Effect of adalimumab on joint disease: features of patients with psoriatic arthritis detected by magnetic resonance imaging
48. Treatment recommendations for psoriatic arthritis
49. Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT)
50. The effect of etanercept on osteoclast precursor frequency and enhancing bone marrow oedema in patients with psoriatic arthritis
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.